Weinsberg

This research focuses on adults with advanced non-small cell lung cancer NSCLC who have been prescribed cemiplimab-based treatments as part of their standard care. The study aims to better understand how cemiplimab regimens are used, their benefits, and safety in real-world clinical practice across Europe. Participants receive cemiplimab either alone or combined with platinum-based chemotherapy. Data is collected during routine clinical visits about every three months while on treatment and then about every six months for up to two years after stopping cemiplimab. The study follows patients from starting cemiplimab until death, loss to follow-up, withdrawal, or the study end, spanning up to 72 months. During the study, participants complete questionnaires and undergo regular clinical assessments at their usual care visits. Researchers monitor overall survival, response rates, duration and timing of responses, progression-free survival, and time to next treatment. Safety is assessed by tracking treatment-related adverse events, immune-related effects, and infusion reactions throughout the study period.